Biomarin Pharmaceutical Inc
General ticker "BMRN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $12.5B
Biomarin Pharmaceutical Inc does not follow the US Stock Market performance with the rate: -29.1%.
Estimated limits based on current volatility of 1.7%: low 64.24$, high 66.40$
Factors to consider:
- Current price 17.2% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [79.99$, 120.55$]
- 2024-12-30 to 2025-12-30 estimated range: [82.78$, 125.71$]
Financial Metrics affecting the BMRN estimates:
- Positive: 0.93 < Non-GAAP EPS, $ of 2.09
- Negative: Operating cash flow per share per price, % of 0.90 <= 2.35
- Positive: -0.96 < Investing cash flow per share, $ of -0.59
- Positive: Interest expense per share, $ of 0.09 <= 0.14
- Positive: -0.25 < Return on assets ratio (scaled to [-100,100]) of 2.39
- Positive: 1.03 < Operating profit margin, % of 6.54
- Negative: Inventory ratio change, % of 2.46 > 1.08
Short-term BMRN quotes
Long-term BMRN plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $1,846.28MM | $2,204.04MM | $2,419.23MM |
| Operating Expenses | $1,928.62MM | $2,054.48MM | $2,261.13MM |
| Operating Income | $-82.34MM | $149.56MM | $158.10MM |
| Non-Operating Income | $6.99MM | $0.01MM | $30.47MM |
| Interest Expense | $15.34MM | $15.97MM | $17.34MM |
| R&D Expense | $628.79MM | $649.61MM | $746.77MM |
| Income(Loss) | $-75.35MM | $149.58MM | $188.56MM |
| Taxes | $-11.27MM | $8.02MM | $20.92MM |
| Profit(Loss) | $-64.08MM | $141.56MM | $167.65MM |
| Stockholders Equity | $4,265.67MM | $4,603.16MM | $4,951.55MM |
| Inventory | $776.67MM | $894.08MM | $1,107.18MM |
| Assets | $6,004.77MM | $6,375.07MM | $6,841.60MM |
| Operating Cash Flow | $304.54MM | $175.90MM | $159.26MM |
| Capital expenditure | $119.22MM | $131.54MM | $107.61MM |
| Investing Cash Flow | $-366.31MM | $-20.03MM | $-111.24MM |
| Financing Cash Flow | $-0.05MM | $-18.65MM | $-18.73MM |
| Earnings Per Share* | $-0.35 | $0.76 | $0.89 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.